HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GW9508

structure in first source

Networked: 22 relevant articles (4 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Methylamines: 15
    - GW9508: 22
- Carboxylic Acids: 973
  - Acyclic Acids
    - Propionates: 988
      - GW9508: 22
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Propionates: 988
      - GW9508: 22

Experts

1.	Nakamoto, Kazuo: 6 articles (01/2018 - 01/2012)
2.	Tokuyama, Shogo: 5 articles (01/2018 - 01/2012)
3.	Kasuya, Fumiyo: 3 articles (12/2014 - 01/2012)
4.	Koyama, Yutaka: 3 articles (01/2013 - 01/2012)
5.	Mankura, Mitsumasa: 3 articles (01/2013 - 01/2012)
6.	Nishinaka, Takashi: 3 articles (01/2013 - 01/2012)
7.	Gong, Yuhang: 2 articles (10/2021 - 01/2020)
8.	He, Ling: 2 articles (10/2021 - 01/2020)
9.	Matsumoto, Kengo: 2 articles (01/2013 - 01/2012)
10.	Ding, Xiaoju: 1 article (05/2022)

Related Diseases

1.	Cognitive Dysfunction 01/01/2020 - "GW9508 ameliorates cognitive impairment via the cAMP-CREB and JNK pathways in APPswe/PS1dE9 mouse model of Alzheimer's disease." 10/15/2021 - "GW9508 ameliorates cognitive dysfunction via the external treatment of encephalopathy in Aβ1-42 induced mouse model of Alzheimer's disease."
2.	Alzheimer Disease (Alzheimer's Disease) 01/01/2020 - "GW9508 ameliorates cognitive impairment via the cAMP-CREB and JNK pathways in APPswe/PS1dE9 mouse model of Alzheimer's disease." 10/15/2021 - "GW9508 ameliorates cognitive dysfunction via the external treatment of encephalopathy in Aβ1-42 induced mouse model of Alzheimer's disease."
3.	Atherosclerosis 08/01/2019 - "Prolonged administration of GW9508 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR1/FFAR4 receptors holds promise for a new approach to the prevention or treatment of atherosclerosis." 08/01/2019 - "The present study investigates the influence of prolonged treatment with GW9508 - agonist of FFAR1 and FFAR4 - on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods. "
4.	Splenomegaly 11/01/2020 - "As for inflammatory outcomes, ALA improved anemia, whereas GW9508 reduced splenomegaly. "
5.	Brain Diseases (Brain Disorder) 10/15/2021 - "GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy. " 10/15/2021 - "GW9508 ameliorates cognitive dysfunction via the external treatment of encephalopathy in Aβ1-42 induced mouse model of Alzheimer's disease."

Related Drugs and Biologics

1.	Lipids
2.	Formaldehyde (Formol)
3.	GW1100
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Interleukin-18 (Interleukin 18)
6.	Dextran Sulfate
7.	Trinitrobenzenesulfonic Acid
8.	Proteins (Proteins, Gene)
9.	Peptides (Polypeptides)
10.	Melanocyte-Stimulating Hormones (MSH)

Related Therapies and Procedures

1.	Spinal Injections